Finally, we found that CD19(-)CD38(hi)CD138(+) PCs had a distinct RNA transcriptome signature and human immunoglobulin heavy chain (VH) repertoire that was relatively uncoupled from other BM PC subsets and probably represents the B cell response's "historical record'' of antigenic exposure. ...
病理免疫组化:弥漫性大B细胞淋巴瘤,非特指型,非生发中心起源(Hans模型),双重表达淋巴瘤;Bcl-2(80%+),Bcl-6(+),CD3(-),CD5(-),CD10(-),CD15(-),CD30(-),CD79a(NS),CD138(-),C-myc(热点40%+),Ki-67(80%+),MUM1(+),PAX5(+)。CD20(+,95%强),CD19(+,95%强),CD22(+,95%强),C...
CD19(-)CD45(low/-)CD38(high)/CD138(+) plasma cells enrich for human tumorigenic myeloma cells 作者:Kim D*; Park C Y; Medeiros B C; Weissman I L 来源:Leukemia, 2012, 26(12): 2530-2537. DOI:10.1038/leu.2012.140 multiple myeloma ...
由于该患者只评估了CD19细胞膜的表达,因此不能排除胞内表达一种可以激活信号通路的截短CD19蛋白。CD19阴性在浆母细胞淋巴瘤中很常见,此类淋巴瘤还同时表达其他浆细胞标记物如CD138或CD38,不表达B细胞标记物如CD20和CD19。该患者未表达...
Here we used CD19, CD38, and CD138 to identify four PC subsets in human bone marrow (BM). We found that the CD19−CD38hiCD138+ subset was morphologically distinct, differentially expressed PC-associated genes, and exclusively contained PCs specific for viral antigens to which the subjects ...
By the classical approach, a CD19/CD45low//CD38high/CD138+ malignant plasma cell, but not the CD19+/CD38low/ memory B cell compartment, is enriched for tumorigenic cells that initiate myeloma in xenografted immunodeficient mice, ... HE Johnsen,M Bogsted,A Schmitz,... - 《Haematologica》...
Simplified flow cytometric immunophenotyping panel for multiple myeloma, CD56/CD19/CD138(CD38)/CD45, to differentiate neoplastic myeloma cells from reactiv... Simplified flow cytometric immunophenotyping panel for multiple myeloma,CD56/CD19/CD138(CD38)/CD45,to differentiate neoplastic myeloma cells from...
A. CD3、CD19、CD20、CD79α、bc1-2阳性 B. CD3、CD7、CD2、CDABE2、CD5阳性 C. CD3、CD4、CD20、CD79α、TdT阳性 D. CD15、CD3、CD68、MPO阳性 E. CD3、CD4、CD5、CD38、CD138阳性 相关知识点: 试题来源: 解析 A.CD3、CD19、CD20、CD79α、bc1-2阳性 反馈...
IgYENPP-1 MHC class II (I-A/I-E)HVEM/TNFRSF14 MS4A1/CD20IgEPlasmablastCD19 Syndecan-1/CD138CD27 Ligand/TNFSF7Plasma CellBCMA/TNFRSF17 IgG2ACD19 IgG2BCD27 Ligand/TNFSF7 IgG3CD38 Ig Lambda C DomainENPP-1 IgMIgE IgYIgG Syndecan-1/CD138IgG...
63.如权利要求59-62中任一项所述的方法,其中,所述的免疫疗法是靶向细胞表面抗原的免疫疗法,所述细胞表面抗原选自包含CD19、CD20、CD22、CD27、CD30、CD33、CD38、CD44v6、CD52、CD64、CD70、CD72、CD123、CD135、CD138、CD220、CD269、CD319、ROR1、ROR2、SLAMF7、BCMA、αvβ3-整联蛋白、α4β1-整...